| 张儒奇;董晓婕;林子悦;朱炳旭;秦天豪;于斌;王荣;孙闵.中药复方靶向菌群治疗腹泻型肠易激综合征的研究进展[J].中医药信息,2023,40(8):78-83 |
| 中药复方靶向菌群治疗腹泻型肠易激综合征的研究进展 |
| Research Progress of Chinese Medicinal Compound Targeting Gut Microbiota in Treatment of IBS－D |
| 投稿时间：2022-12-22 录用日期：2023-01-11 |
| DOI：10.19656/j.cnki.1002-2406.20230812 |
| 中文关键词: 中药 腹泻型肠易激综合征 肠道菌群 |
| 英文关键词: Chinese medicinal IBS－D Gut microbiota |
| 基金项目:国家自然科学基金项目（81603509）；山东省中医药重点学科建设项目[鲁卫中医药科教字[2022]4号]；济宁医学院中西医结合治疗脾胃病创新团队项目（jy201918）；济宁医学院大学生创新训练计划项目（cx2021144） |
|
| 摘要点击次数: 99 |
| 全文下载次数: 76 |
| 中文摘要: |
| 腹泻型肠易激综合征（diarrhea-predominant irritable bowel syndrome,IBS-D）是临床常见的胃肠道疾病之一。现代医学常采取饮食干预、药物治疗以及认知行为疗法等方式，但存在较多不良反应，且易复发，而中医药治疗IBS-D安全有效。目前肠道菌群与IBS-D之间的相互作用关系受到广泛重视，本文综述国内外相关研究文献，发现肠道菌群作为脑肠交互机制的新中介，在免疫和神经内分泌系统等方面发挥重要作用；中药复方可靶向肠道菌群，影响厚壁菌门、拟杆菌门、普雷沃菌属以及双歧杆菌、乳酸杆菌、大肠杆菌等菌群组成结构变化，并通过抗炎、降低内脏高敏性、恢复肠道黏膜屏障、调节胃肠动力等作用途径，有效缓解IBS-D临床症状。 |
| 英文摘要: |
| Diarrhea-predominant irritable bowel syndrome(IBS-D) is one of the common clinical gastrointestinal diseases. In terms of treatment, modern medicine often adopts diet intervention, drug treatment and cognitive behavioral therapy, but there are many adverse reactions and easy to relapse, whereas Chinese medicinal treatment for IBS-D is safe and effective. At present, the interaction between gut microbiota and IBS-D has received extensive attention. This study reviewed the related literature at home and abroad, and found that gut microbiota, as a new intermediary of brain-gut interaction mechanism, played an important role in immune system and neuroendocrine system. Chinese medicinal compound can target the gut microbiota, affect the composition and the structure of Firmicutes, Bacteroideta, Prevotella, Bifidobacterium, Lactobacillus, Escherichia coli and other gut microbiota, and effectively alleviate the clinical symptoms of IBS-D by reducing inflammation, inhibiting visceral hypersensitivity, restoring intestinal mucosal barrier and regulating gastrointestinal motility. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
